Drugs / cytomegalovirus pp65-specific cytotoxic T lymphocytes
cytomegalovirus pp65-specific cytotoxic T lymphocytes
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00769613 | Aug 2008 → Aug 2014 | cancer | Milton S. Hershey Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT00509691 | Jun 2007 → Dec 2011 | cancer | University of Louisville | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cytomegalovirus pp65-specific cytotoxic T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00769613 ↗ |
| Known as | CMV pp65 CTL | “Characterize the levels of CMV DNA in recipients of CMV pp65 CTL and observe whether the CTL infusion has any impact on the level of virus.” NCT00509691 ↗ |
| Known as | CMV pp65 Specific Cytotoxic T Lymphocytes | “A Phase I Trial to Examine the Safety, Clinical, Immunologic and Virologic Effects of CMV pp65 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell...” NCT00509691 ↗ |
| Action | Deplete | “may kill cells that are infected with cytomegalovirus” NCT00769613 ↗ |
| Modality | Cell therapy | “cytomegalovirus (CMV) pp65 cytotoxic T-cell infusion” NCT00509691 ↗ |
| Route | Other | “infusing cytomegalovirus (CMV) pp65-specific cytotoxic T-lymphocytes (CTL)” NCT00509691 ↗ |